Table 3.
Trigger prevalence within 1 y, by cancer type and metastatic status
| Trigger |
Breast cancer n = 124 253 |
Colorectal cancer n = 52 383 |
Lung cancer n = 51 311 |
Prostate cancer n = 94 940 |
||||
|---|---|---|---|---|---|---|---|---|
|
Nonmetastatic n = 97 462 |
Metastatic n = 26 791 |
Nonmetastatic n = 33 712 |
Metastatic n = 18 671 |
Nonmetastatic n = 21 142 |
Metastatic n = 30 169 |
Nonmetastatic n = 84 140 |
Metastatic n = 10 800 |
|
| Any trigger | 10.2% (9958/97 462) | 30.9% (8275/26 791) | 19.2% (6488/33 712) | 41.4% (7738/18 671) | 32.8% (6930/21 142) | 50.2% (15 157/30 169) | 5.9% (4987/84 140) | 24.6% (2654/10 800) |
| Anticoagulation | 0.1% (77/87 345) | 0.2% (56/25501) | 0.2% (63/32 893) | 0.5% (97/18 217) | 0.3% (49/17 799) | 0.4% (109/26 252) | 0.1% (49/63 869) | 0.2% (17/9818) |
| Bacteremia/positive blood culture | 0.3% (279/87 345) | 1.4% (361/25 501) | 1.1% (355/32 893) | 3.1% (571/18 217) | 1.6% (279/17 799) | 2.4% (617/26 252) | 0.3% (183/63 869) | 1.6% (154/9818) |
| Abnormal serum bicarbonate | 1.8% (1575/87 345) | 5.0% (1285/25 501) | 3.9% (1287/32 893) | 9.3% (1700/18 217) | 4.7% (831/17 799) | 7.3% (1917/26 252) | 1.9% (1239/63 869) | 6.3% (619/9818) |
| Blood transfusion | 1.9% (1682/87 345) | 8.8% (2234/25 501) | 2.6% (854/32 893) | 9.6% (1740/18 217) | 12.2% (2172/17 799) | 23.2% (6087/26 252) | 0.6% (399/63 869) | 7.6% (749/9818) |
| C. difficile positive | 0.3% (296/87 345) | 1.1% (271/25 501) | 1.1% (362/32 893) | 2.5% (450/18 217) | 1.3% (227/17 799) | 1.8% (480/26 252) | 0.2% (122/63 869) | 0.7% (66/9818) |
| Non‐contrast chest CT following XRT | 1.6% (847/53 272) | 3.0% (496/16 658) | 2.1% (128/6022) | 4.1% (216/5229) | 10.3% (977/9523) | 11.3% (2339/20 735) | 1.1% (422/37 290) | 4.9% (218/4425) |
| Elevated creatinine | 0.1% (131/97 462) | 0.5% (136/26 791) | 0.3% (85/33 712) | 0.8% (158/18 671) | 0.6% (125/21 142) | 1.0% (315/30 169) | 0.1% (67/84 140) | 0.4% (43/10 800) |
| Hypoxemia/low oximetry | 1.0% (992/97 462) | 4.0% (1078/26 791) | 2.8% (937/33 712) | 5.9% (1103/18 671) | 12.2% (2572/21 142) | 16.3% (4927/30 169) | 1.2% (1050/84 140) | 4.6% (493/10 800) |
| Contact precautions/isolation | 6.0% (2630/43 825) | 9.5% (2147/22 616) | 4.1% (483/11 816) | 6.0% (931/15 614) | 6.2% (732/11 732) | 8.0% (1976/24 672) | 1.2% (367/29 511) | 3.6% (322/8924) |
| Nasogastric tube | < 11 events | < 11 events | 0.5% (124/27 078) | 0.6% (68/10 600) | < 11 events | < 11 events | 0.1% (29/38 298) | < 11 events |
| Nephrology consult | 0.3% (254/97 462) | 1.3% (350/26 791) | 1.4% (485/33 712) | 3.1% (577/18 671) | 1.3% (279/21 142) | 2.1% (645/30 169) | 0.6% (541/84 140) | 2.6% (284/10 800) |
| Neutropenic fever | 4.0% (1765/43 825) | 6.8% (1535/22 616) | 4.5% (528/11 816) | 5.7% (894/15 614) | 6.7% (788/11 732) | 7.4% (1814/24 672) | 0.6% (173/29 511) | 2.6% (231/8924) |
| Percutaneous drain | 0% (25/68 318) | 0.1% (18/15 425) | 0.8% (206/27 078) | 2.4% (252/10 600) | 0.6% (48/8144) | 0.5% (25/5160) | 0.3% (96/38 298) | 0.6% (12/2060) |
| Abnormal serum potassium | 2.5% (2218/87 345) | 8.7% (2211/25 501) | 7.3% (2417/32 893) | 17.7% (3233/18 217) | 8.1% (1445/17 799) | 13.9% (3656/26 252) | 1.8% (1135/63 869) | 6.9% (674/9818) |
| Press ulcer | 0.3% (230/68 318) | 0.6% (85/15 425) | 1.2% (313/27 078) | 1.5% (154/10 600) | 1.0% (78/8144) | 0.9% (45/5160) | 0.2% (95/38 298) | 0.8% (17/2060) |
| Return to OR or IR | 0.1% (63/68 318) | 0.2% (37/15 425) | 2.4% (638/27 078) | 3.7% (392/10 600) | 0.4% (33/8144) | 0.4% (21/5160) | 0.6% (229/38 298) | 0.7% (14/2060) |
Values shown in the table are prevalence rates and the number of patients with a trigger within an exposure window divided by the number exposed in parentheses.